Pulsenmore Reports 374% Revenue Surge on GE Settlement, FDA Clearance
Event summary
- Pulsenmore reported $12.5M in 2025 revenue, up 374% YoY, driven by a $9.6M GE settlement.
- Net loss improved to $5M from $10M in 2024, with $21.7M in liquid assets as of December 31, 2025.
- Secured FDA clearance for remote-use prenatal ultrasound and EU MDR CE Certification for its ES product.
- Initial U.S. commercial programs validating home-use ultrasound integration with clinical workflows.
- Gross margin expanded to 84% from 37% YoY, despite operating expenses rising to $14.4M.
The big picture
Pulsenmore's 2025 results highlight a transition from regulatory milestones to commercial execution in the remote prenatal diagnostics space. The GE settlement provided a significant revenue boost, but the company's strategic focus on scaling U.S. infrastructure and expanding clinical partnerships will determine its long-term market positioning. With $21.7M in liquid assets and improved financial metrics, Pulsenmore is now positioned to compete in a rapidly evolving telemedicine landscape.
What we're watching
- Commercial Momentum
- Whether Pulsenmore can sustain early validation from providers and health systems into broader market adoption.
- Recurring Revenue
- The pace at which Pulsenmore strengthens recurring revenue streams amid disciplined investment.
- Regulatory Expansion
- How Pulsenmore leverages FDA and EU clearances to penetrate the largest prenatal diagnostics markets.
Related topics